Affiliation:
1. Baker Heart and Diabetes Institute Melbourne VIC
2. Menzies Research Institute Tasmania University of Tasmania Hobart TAS
3. The University of Queensland Brisbane QLD
4. Monash Medical Centre Monash University Melbourne VIC
5. Monash University Melbourne VIC
6. The University of Western Australia Perth WA
Abstract
AbstractObjectivesTo compare the cost‐effectiveness of coronary artery calcium (CAC) score‐guided statin therapy criteria and American College of Cardiology/American Heart Association (ACC/AHA) guidelines (10‐year pooled cohort equation [PCE] risk ≥ 7.5%) with selection according to Australian guidelines (5‐year absolute cardiovascular disease risk [ACVDR] ≥ 10%), for people with family histories of premature coronary artery disease.Study design, settingMarkov microsimulation state transition model based on data from the Coronary Artery calcium score: Use to Guide management of Hereditary Coronary Artery Disease (CAUGHT‐CAD) trial and transition probabilities derived from published statin prescribing and adherence outcomes and clinical data.Participants1083 people with family histories of premature coronary artery disease but no symptomatic cardiovascular disease.Main outcome measuresRelative cost‐effectiveness over fifteen years, from the perspective of the Australian health care system, compared with usual care (Australian guidelines), assessed as incremental cost‐effectiveness ratios (ICERs), with a notional willingness‐to‐pay threshold of $50 000 per quality‐adjusted life‐year (QALY) gained.ResultsApplying the Australian guidelines, 77 people were eligible for statin therapy (7.1%); with ACVDR 5‐year risk ≥ 2% and CAC score > 0, 496 people (46%); with ACVDR 5‐year risk ≥ 2% and CAC score ≥ 100, 155 people (14%); and with the ACC/AHA guidelines, 256 people (24%). The ICERs for CAC‐guided selection were $33 108 (CAC ≥ 100) and $53 028 per QALY gained (CAC > 0); the ACC/AHA guidelines approach (ICER, $909 241 per QALY gained) was not cost‐effective. CAC score‐guided selection (CAC ≥ 100) was cost‐effective for people with 5‐year ACVDR of at least 5%.ConclusionExpanding the number of people at low to intermediate CVD risk eligible for statin therapy should selectively target people with subclinical atherosclerosis identified by CAC screening. This approach can be more cost‐effective than simply lowering treatment eligibility thresholds.
Funder
National Health and Medical Research Council
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献